Enyo Pharma   Report issue

For profit Phase 2
Founded: Lyon France (2014)

Organization Overview

First Clinical Trial
2016
NCT03110276
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Enyo Pharma

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 4